Ophthalmology Search
Ophthalmology Ophthalmology
conjunctivitis%20-%20viral
CONJUNCTIVITIS - VIRAL
Viral conjunctivitis is the inflammation of the conjunctiva of viral etiology.
Signs and symptoms include unilateral or bilateral eye redness, foreign body sensation and follicular conjunctival reaction.
It may be caused by adenovirus, herpes simplex or molluscum contagiosum.

Introduction

  • A highly contagious acute conjunctival infection usually caused by adenovirus 
  • May be a part of a viral prodrome or is the only symptom of a viral illness 

Definition

  • Inflammation of the conjunctiva of viral etiology 

Signs and Symptoms

  • Symptoms become worse for the first 3-5 days then gradually resolve in 2-3 weeks
  • Common upper respiratory coinfection
  • Mild to moderate eye redness & pruritus
  • Watery eye discharge
  • Rare bilateral eye involvement
  • Foreign body sensation
  • Follicular conjunctival reaction
  • Common lymphadenopathy
Editor's Recommendations
Most Read Articles
Molecule length affects health impact of saturated fatty acids
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
Olanzapine improves weight in adult outpatients with anorexia nervosa
5 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Time and size key to functional recovery in thrombectomy for large-core stroke
Pearl Toh, 2 days ago
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Secukinumab produces durable remission in psoriatic arthritis
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.